The vaccine, called Prevnar, is already approved for use in adults 50 years and older, as well as children between the ages of six weeks and 17 years.
Prevnar protects against invasive diseases caused by 13 Streptococcus pneumonia strains.
The FDA decided to expand the vaccine’s use after studying results from a late-stage trial that included adults who had not yet been vaccinated against the disease.
More articles on supply chain:
GE stakes claim on cell therapy market with Biosafe acquisition
10 costliest medical conditions
FDA panel endorses Amgen’s biosimilar version of Humira
